Key Takeaway
Most adults lose approximately 15% of their body weight on Wegovy over 68 weeks. Learn about STEP trial results, weight loss timelines, and factors that shape individual outcomes.
Most adults lose approximately 15% of their body weight on Wegovy (semaglutide 2.4 mg) over 68 weeks. In the STEP 1[1] clinical trial, the average participant lost 14.9% of their starting body weight, which amounted to roughly 33.7 pounds. About one in three participants lost 20% or more.
Wegovy Weight Loss Results from Clinical Trials
Wegovy is the brand name for semaglutide 2.4 mg, the highest available dose of this GLP-1 receptor agonist, FDA-approved specifically for chronic weight management. It's a compounded formulation containing Ozempic but formulated and dosed specifically for weight loss rather than diabetes. The STEP clinical trial program provides thorough weight loss data.
STEP 1: Primary Weight Loss Data
STEP 1 was the important trial that led to Wegovy's FDA approval. It enrolled 1,961 adults[1] with a BMI of 30 or higher (or 27+ with a weight-related condition) and no diabetes. Key findings at 68 weeks:
- Average weight loss: 14.9% of body weight (vs. 2.4% with placebo)
- Average pounds lost: approximately 33.7 pounds
- 86.4% of participants lost at least 5%[1] of body weight
- 69.1% lost at least 10%
- 50.5% lost at least 15%
- 32.0% lost 20% or more
Results Across the STEP Program
- STEP 2[2] (adults with type 2 diabetes): Average weight loss of 9.6% at 68 weeks. The diabetes[2] population consistently loses less, likely due to metabolic factors including insulin resistance.
- STEP 3[3] (with intensive behavioral therapy): Average weight loss of 16.0%, demonstrating that structured lifestyle intervention boosts results beyond medication alone.
- STEP 5[4] (2-year extension): Average weight loss of 15.2% at 104 weeks, confirming that results are sustained with continued use over two years[4].
- STEP 8[5] (vs. liraglutide/Saxenda): Wegovy produced 15.8% weight loss vs. 6.4% for liraglutide, showing substantially greater efficacy than the older GLP-1 weight loss medication.
The SELECT Cardiovascular Trial[6]
The SELECT trial studied Wegovy in 17,604 adults with obesity and established cardiovascular disease but without diabetes. Beyond confirming weight loss of approximately 9.4% (in a population with higher comorbidity burden), the trial demonstrated a 20% reduction in major adverse cardiovascular[6] events. This finding expanded the recognized benefits of Wegovy beyond weight loss alone.
What to Expect in Pounds
Based on the 15% average weight loss from STEP 1:
- Starting at 180 pounds: approximately 27 pounds lost
- Starting at 220 pounds: approximately 33 pounds lost
- Starting at 260 pounds: approximately 39 pounds lost
- Starting at 300 pounds: approximately 45 pounds lost
Weight Loss Timeline
Wegovy uses a 16-week dose escalation schedule before reaching the full 2.4 mg maintenance dose:
- Month 1 (0.25 mg): Introductory dose. Weight loss is minimal, typically 2-4 pounds. Appetite reduction begins.
- Months 2-4 (0.5 mg, 1.0 mg, 1.7 mg): Weight loss accelerates with each dose increase. Most people have lost 4-8% of body weight by the end of month 4.
- Months 5-12 (2.4 mg maintenance): The steepest weight loss period. Monthly loss averages 2-4 pounds.
- Months 12-18: Weight loss gradually slows and plateaus. Most of the total benefit is achieved by this point.
What Influences Individual Results
- Lifestyle changes: Every STEP trial participant received counseling on reduced-calorie diet and physical activity. Patients who actively follow dietary guidance tend to lose more.
- Diabetes status: Type 2 diabetes reduces expected weight loss by roughly 5 percentage points.
- Dose tolerance: A small percentage of patients can't reach the full 2.4 mg dose due to GI side effects and stay on a lower dose, which produces less weight loss.
- Starting BMI: Higher starting weights yield more pounds lost, though percentage loss is relatively consistent across BMI categories.
- Biological variability: About 14% of STEP 1 participants did not achieve the 5% weight loss threshold, highlighting that individual response varies.
What to Consider
Wegovy is a long-term medication. The STEP 4 trial[7] showed that participants who stopped semaglutide after reaching their weight loss goal regained approximately two-thirds of lost weight within a year. Planning for sustained treatment is important for maintaining results. For a complete cost breakdown, see our cheapest GLP-1 without insurance.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Weight loss isn't purely linear. Plateaus lasting several weeks are normal and don't mean the medication has stopped working. Tracking trends over months rather than individual weigh-ins gives a more accurate picture of progress.
Your physician should monitor not just weight but also blood pressure, metabolic markers, and overall health improvements. Many patients see benefits in blood pressure, cholesterol, joint pain, and energy levels well before reaching their target weight.
Frequently Asked Questions
Do I need a prescription for How Much Weight Will I?
Yes, GLP-1 receptor agonists require a prescription from a licensed healthcare provider. You can obtain a prescription through an in-person visit or a telehealth consultation with a qualified provider.
What are the most common side effects of How Much Weight Will I?
The most frequently reported side effects include nausea (especially during dose escalation), decreased appetite, and mild gastrointestinal discomfort. These typically improve as your body adjusts to the medication over 2-4 weeks.
How long does it take for How Much Weight Will I to show results?
Most patients begin noticing effects within 4-8 weeks of starting treatment. Full results for weight management typically appear over 12-16 weeks with consistent use and lifestyle modifications.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2023;327(2):138-150. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. [PubMed | ClinicalTrials.gov | DOI]
Start Your Wegovy process with FormBlends
FormBlends connects you with licensed physicians who specialize in GLP-1 therapy for weight management. Your treatment plan includes a complete medical evaluation, guided dose titration, and ongoing clinical support to help you achieve and maintain your results. Start your consultation today.